John Bell - Roche Holding Non-Executive Director

RHHBF Stock  USD 268.90  4.15  1.57%   

Director

Prof. John Irving Bell has served as NonExecutive Independent Director of Roche Holding Ltd since 2001. In addition, he acts as Member of the Audit Committee of the Company. In 1975, he gained a Bachelor of Medical Science with Honors from the University of Alberta. In 1976, Prof. Sir Bell gained a Bachelor of Arts with Honors in Physiological Sciences from Magdalen College, Oxford University. In 1979, he gained a Bachelor of Medicine and Bachelor of Surgery from Magdalen College, Oxford University. In 1990, he gained a Doctor of Medicine from Magdalen College, Oxford University. From 1979 until 1982, he carried out postgraduate clinical training in Oxford and London. From 1982 until 1987, Prof. Sir Bell was Clinical Fellow in the Department of Medicine at Stanford University and also Postdoctoral Fellow in the Department of Medical Microbiology at Stanford University. From 1987 until 1989, he was Wellcome Senior Clinical Fellow and Honorary Consultant Physician in the Nuffield Departments of Clinical Medicine and Surgery at John Radcliffe Hospital, Oxford. From 1989 until 1992, he was University Lecturer at the Nuffield Department of Clinical Medicine at Oxford University. From 1992 until 2002, he was Nuffield Professor of Clinical Medicine at Oxford University. Since 2002, Prof. Bell was Regius Professor of Medicine at Oxford University. He has also been Honorary Consultant Physician at Oxford Radcliffe NHS Trust since 1987 Nuffield Professor of Clinical Medicine Chairman at the Department of Medicine, Oxford University School of Medicine, since 1992 Founder of the Wellcome Trust Centre for Human Genetics since 1993 Chairman of the Partnership Board at the Oxford Centre for Diabetes, Endocrinology and Metabolism since 1999 Chairman of the Trials and Epidemiology Building, Oxford since 1999 and President of the Academy of Medical Sciences since 2006. He was knighted in the 2008 Honors list for Services to Medicine. since 2001.
Age 65
Tenure 23 years
Professional MarksPh.D
Phone41 61 688 11 11
Webhttps://www.roche.com

Roche Holding Management Efficiency

The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 16.08 B in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Roche Holding AG has a current ratio of 1.09, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Roche Holding until it has trouble settling it off, either with new capital or with free cash flow. So, Roche Holding's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Roche Holding AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Roche to invest in growth at high rates of return. When we think about Roche Holding's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Christine SeidmanMerck Company
68
Nazneen RahmanAstraZeneca PLC
N/A
Carolyn BertozziEli Lilly And
53
Deborah DiSanzoAstraZeneca PLC
58
Susan LindquistJohnson Johnson
65
Peter VoserRoche Holding
59
William KaelinEli Lilly And
63
Ralph AlvarezEli Lilly And
63
Scott DavisJohnson Johnson
66
Paul RothmanMerck Company
63
Richard LiftonRoche Holding AG
65
Eugene WashingtonJohnson Johnson
67
Craig ThompsonMerck Company
64
William PerezJohnson Johnson
71
Cornelia BargmannAstraZeneca PLC ADR
N/A
Ton BuechnerNovartis AG ADR
55
Mark McClellanJohnson Johnson
57
Pierre LandoltNovartis AG ADR
70
Claudia DyckerhoffRoche Holding AG
51
Simon MoroneyNovartis AG ADR
62
Enrico VanniNovartis AG
67
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. ROCHE HOLDINGS operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 100920 people. Roche Holding AG [RHHBF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Roche Holding AG Leadership Team

Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Bruno Eschli, Head Relations
Silvia Ayyoubi, Head of Group HR
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Thomas Schinecker, Chief Diagnostics
Beatrice Mauro, Non-Executive Director
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering
Gottlieb Keller, General Counsel and Corporate Secretary
Urs Jaisli, Chief Compliance Officer
Daniel ODay, COO of Pharmaceuticals division
Claudia Bockstiegel, G Counsel
DeAnne Julius, Non-Executive Director
Johannes MD, Head Devel
Karl Mahler, Head of Investor Relations
Andre Hoffmann, Non-Executive Vice Chairman of the Board
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Claudia Dyckerhoff, Non-Executive Director
Fritz Gerber, Honorary Chairman of the Board
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
Julie Brown, Non-Executive Director
Richard Lifton, Non-Executive Director
Paul Bulcke, Non-Executive Director
Christoph Franz, Non-Executive Director
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office
Pascale Schmidt, Chief Officer
Pius Baschera, Non-Executive Director
Peter Voser, Non-Executive Director
Bernard Poussot, Non-Executive Director
John Bell, Non-Executive Director
Andreas Oeri, Non-Executive Director
Alan Hippe, CFO and IT Officer
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED)
F Hoffmann, IR Contact Officer
Severin Schwan, CEO and Director
Anita Hauser, Non-Executive Director
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics

Roche Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Roche Holding AG information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Roche OTC Stock analysis

When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Please note, there is a significant difference between Roche Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if Roche Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Roche Holding's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.